Stellantis Trails Its Rival on Key Metrics but Offers Compelling Upside for Patient Investors

Intuitive Surgical Stock Is Up Over 400%. Here's Why It's Still a No-Brainer Buy.

Intuitive Surgical has been a huge winner over the long term, but there's a potential opening for new investors right now.

Viking Therapeutics (NASDAQ: VKTX) Faces Uphill Battle In $150 Billion GLP-1 Race Toward 2030

Viking Therapeutics (NASDAQ: VKTX) is positioning itself as a challenger in the obesity drug market, competing directly against industry titans Eli Lilly and Novo Nordisk. Both Eli Lilly and Novo Nordisk have generated enormous revenues from their respective weight-loss medicines, setting a high commercial bar for any new entrant. Viking’s lead drug candidate, VK2735, has [] The post Viking Therapeutics (NASDAQ: VKTX) Faces Uphill Battle In 150 Billion GLP-1 Race Toward 2030 appeared first on Foreign Policy Journal.

After Harvey, vertical AI’s next $10B winner might be in agriculture

In legal, Harvey crossed an 11 billion valuation and Legora is racing to claim the European market behind it. In healthcare, Abridge has built a multi-billion-dollar business turning clinical conversations into structured medical records. In customer service, Sierra is now valued at over 15 billion, making it one of the fastest companies in AI history [] This story continues at The Next Web

Morgan Stanley reiterates Overweight on Nvidia stock citing diversified growth

Morgan Stanley reiterates Overweight on Nvidia stock citing diversified growth

Who owns NZ GPs: The private equity giants, Kiwi corporates and the doctors

Who owns NZ GPs: The private equity giants, Kiwi corporates and the doctors

Cardinal Health: Why This Essential Healthcare Distributor Deserves A Buy Rating

Cardinal Health: Why This Essential Healthcare Distributor Deserves A Buy Rating

What's new with iPhone 18 Pro Max? Guess correctly for a chance to win an Apple Watch

Each prediction you get right gives an entry into the grand prize drawing.

The Hill Launching Premium Subscription Product (Exclusive)

The new service, The Hill Insider, is Nexstar's first major foray into direct-to-consumer subscription offerings.

Investigations launched over mobile fees and FIFA ticket fiasco: CBC's Marketplace Cheat Sheet

The CBC's Marketplace rounds up the consumer and health news you need from the week.

Why U.S. pharma giants are betting bigger on China's innovation ecosystem?

From AI-assisted high-complexity cardiovascular interventions—where digital algorithms pre-simulate intricate surgical workflows, accurately predict intraoperative risks, and tailor personalized treatment plans to significantly boost procedural efficiency—to AI-powered FFRangio systems that slash measurement time from 20 minutes to just four... As China, the world's second-largest pharmaceutical market, is rapidly transcending its traditional role from a low-cost manufacturing base to a co-developer of cutting-edge therapies and a vital node in global RD networks, an increasing number of multinational pharmaceutical companies are reshaping their investment and partnership strategies on the ground.

SpaceX Has 'Tremendous' Earnings Power, Say Clear Street Analysts

Brian Dobson, managing director senior analyst, and Greg Pendy, director equity analyst, at Clear Street discuss their buy rating on SpaceX and say that they're looking at the rocket business as a 'placeholder' for other growing parts of the business like Starlink or xAI. (Source: Bloomberg)

Are the markets witnessing ‘AI fatigue’? Jefferies says US tech earnings to test investment cycle

Report says investors now focused on quarterly results of four major US hyperscalers - Alphabet, Amazon, Meta and Microsoft

DEI: Morgan Stanley initiates coverage with “overweight” recommendation and price target of €27

DEI strengthens its position among international investors’ preferences, as investments in renewable energy sources, grids and the group’s transformation create expectations for higher profitability and further growth momentum The post DEI: Morgan Stanley initiates coverage with “overweight” recommendation and price target of 27 appeared first on ProtoThema English.

The banks that will pay you £200 or more to switch – and how to make £1,000 for free

Switching account can reward savers with a big bonus. Here's how the biggest offers compare

Health company accused of using fake doctors for sales

Australians with diabetes, heart disease, obesity and menopause paid thousands and spoke with fake doctors who said their lives were at risk, a watchdog claims.

How Kalshi infects the news

After inking financial deals with CNBC and CNN, Kalshi's prediction markets have become ubiquitous on cable news.